Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06423781). This is a study registration, not published results. Lead sponsor: Biohaven Therapeutics Ltd.. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 233 participants (ACTUAL). Conditions: Major Depressive Disorder. Interventions: DRUG: BHV-7000. Primary outcome measures: Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication , Up to 104 weeks; Number of Participants With Clinically Significant Laboratory Abnormalities , Up to 104 weeks; Number of Participants With Vital Sign Abnormalities , Up to 104 weeks; Number of Participants With Electrocardiogram (ECG) Abnormalities specific to QTc elevation , Up to 104 weeks. Brief summary: The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).